Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.

Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C.

J Clin Oncol. 2015 Dec 1;33(34):4093-8. doi: 10.1200/JCO.2015.61.6490. Epub 2015 Nov 2.

PMID:
26527781
2.

Optimisation of the continuum of supportive and palliative care for patients with breast cancer in low-income and middle-income countries: executive summary of the Breast Health Global Initiative, 2014.

Distelhorst SR, Cleary JF, Ganz PA, Bese N, Camacho-Rodriguez R, Cardoso F, Ddungu H, Gralow JR, Yip CH, Anderson BO; Breast Health Global Initiative Global Summit on Supportive Care and Quality of Life Consensus Panel Members.

Lancet Oncol. 2015 Mar;16(3):e137-47. doi: 10.1016/S1470-2045(14)70457-7. Review.

PMID:
25752564
3.

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC).

Karthaus M, Tibor C, Lorusso V, Singh-Arora R, Filippov A, Rizzi G, Borroni ME, Rossi G, Grunberg SM.

Support Care Cancer. 2015 Oct;23(10):2917-23. doi: 10.1007/s00520-015-2657-1. Epub 2015 Feb 28.

4.

Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung.

Sonis S, Elting L, Keefe D, Nguyen H, Grunberg S, Randolph-Jackson P, Brennan M; TRIAD Burden of Illness Investigators.

Support Care Cancer. 2015 Feb;23(2):433-9. doi: 10.1007/s00520-014-2395-9. Epub 2014 Aug 16.

PMID:
25123194
5.

Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.

Keefe DM, Elting LS, Nguyen HT, Grunberg SM, Aprile G, Bonaventura A, Selva-Nayagam S, Barsevick A, Koczwara B, Sonis ST.

Cancer Chemother Pharmacol. 2014 Oct;74(4):675-80. doi: 10.1007/s00280-014-2526-5. Epub 2014 Jul 25.

PMID:
25055935
6.

Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Cardoso F, Bese N, Distelhorst SR, Bevilacqua JL, Ginsburg O, Grunberg SM, Gralla RJ, Steyn A, Pagani O, Partridge AH, Knaul FM, Aapro MS, Andersen BL, Thompson B, Gralow JR, Anderson BO.

Breast. 2013 Oct;22(5):593-605. doi: 10.1016/j.breast.2013.07.050. Epub 2013 Aug 31. Review.

PMID:
24001709
7.

Emerging treatments in chemotherapy-induced nausea and vomiting.

Grunberg SM, Slusher B, Rugo HS.

Clin Adv Hematol Oncol. 2013 Feb;11(2 Suppl 1):1-18; quiz 2 p following 18. Review.

PMID:
23598819
8.

Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kinetics.

Toth MJ, Miller MS, Callahan DM, Sweeny AP, Nunez I, Grunberg SM, Der-Torossian H, Couch ME, Dittus K.

J Appl Physiol (1985). 2013 Apr;114(7):858-68. doi: 10.1152/japplphysiol.01474.2012. Epub 2013 Feb 14.

9.

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.

Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D.

Support Care Cancer. 2013 May;21(5):1453-60. doi: 10.1007/s00520-012-1691-5. Epub 2013 Jan 26.

10.

New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.

Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD; Alliance for Clinical Trials in Oncology.

Genes Chromosomes Cancer. 2013 Apr;52(4):385-401. doi: 10.1002/gcc.22036. Epub 2012 Dec 10.

11.

Optimal management of malignant pleural effusions (results of CALGB 30102).

Demmy TL, Gu L, Burkhalter JE, Toloza EM, D'Amico TA, Sutherland S, Wang X, Archer L, Veit LJ, Kohman L; Cancer and Leukemia Group B.

J Natl Compr Canc Netw. 2012 Aug;10(8):975-82.

PMID:
22878823
12.

Patient-centered management of chemotherapy-induced nausea and vomiting.

Grunberg S.

Cancer Control. 2012 Apr;19(2 Suppl):10-5. Review.

13.

Improving control of chemotherapy-induced nausea and vomiting.

Grunberg S.

Cancer Control. 2012 Apr;19(2 Suppl):2. No abstract available.

14.

Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.

Schwartzberg LS, Grunberg SM, Kris MG.

Clin Adv Hematol Oncol. 2011 Nov;9(11 Suppl 27):1-14; quiz 15-6.

PMID:
22362372
15.

Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.

Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D.

J Natl Compr Canc Netw. 2012 Feb;10(2):149-57.

PMID:
22308514
16.

Chemotherapy-induced nausea and vomiting incidence and prevalence.

Grunberg SM.

Am Soc Clin Oncol Educ Book. 2012:541-3. doi: 10.14694/EdBook_AM.2012.32.541.

17.

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ; Cancer and Leukemia Group B.

Cancer. 2012 Sep 1;118(17):4139-47. doi: 10.1002/cncr.26732. Epub 2011 Dec 16.

18.

Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).

Romanus D, Kindler HL, Archer L, Basch E, Niedzwiecki D, Weeks J, Schrag D; Cancer and Leukemia Group B.

J Pain Symptom Manage. 2012 Feb;43(2):205-17. doi: 10.1016/j.jpainsymman.2011.09.001. Epub 2011 Nov 21.

19.

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.

Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT.

Int J Surg. 2012;10(1):28-55. doi: 10.1016/j.ijsu.2011.10.001. Epub 2011 Oct 12. Review.

20.

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.

Schulz KF, Altman DG, Moher D; CONSORT Group.

Int J Surg. 2011;9(8):672-7. doi: 10.1016/j.ijsu.2011.09.004. Epub 2011 Oct 13. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk